IP Library Granted Patent US 11,426,438
Granted Patent B2
US 11,426,438 · App. 16/279,481 · Granted Aug 30, 2022

Method for treating arthritis with Boswellia serrata extracts

Inventors: Ganga Raju Gokaraju (Vijayawada, IN); Rama Raju Gokaraju (Vijayawada, IN); Venkata Kanaka Ranga Raju Gokaraju (Vijayawada, IN); Trimurtulu Golakoti (Vijayawada, IN); Kiran Bhupathiraju (Vijayawada, IN); Venkata Krishna Raju Alluri (Vijayawada, IN)
Assignee: LAILA NUTRACEUTICALS
A61K36/324
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,426,438
App. No.
16/279,481
Granted
Aug 30, 2022
Kind
B2
Abstract

Synergistic nutraceutical or pharmaceutical anti-inflammatory compositions include a therapeutically effective combination of: an extract selectively enriched in 3-O-acetyl-11-keto-β-boswellic acid (AKBA) derived from Boswellia serrata ; and a Boswellia serrata non-acidic resin extract (BNRE). The compositions can be used to prevent, control and treat inflammation and several inflammatory related diseases including asthma, osteoarthritis, rheumatoid arthritis, and/or endothelial dysfunction. The invention further discloses the amelioration of pro-inflammatory biomarker proteins or molecules, whose expression/production is altered during inflammatory diseases.

Claims (19)

1. A method for treating a disease in a subject in need thereof, said method comprising:

administering to the subject a therapeutically effective amount of a combination of:

from 10% to 90% by weight of the combination of a Boswellia serrata extract selectively enriched in 3-O-acetyl-11-keto-β-boswellic acid (AKBA); and

from 10% to 90% by weight of the combination of a Boswellia serrata resin non-acidic, water-immiscible organic solvent extract (BNRE) obtained by selectively removing acidic compounds from a Boswellia serrata gum resin extract;

wherein said disease is rheumatoid arthritis, juvenile rheumatoid arthritis, psoriatic arthritis, osteoarthritis, refractory rheumatoid arthritis, chronic non-rheumatoid arthritis, or a combination thereof.

2. The method according to claim 1 , wherein said therapeutically effective amount is effective to ameliorate expression or production of at least one inflammatory marker selected from the group consisting of 5-lipoxygenase (5-LOX), 5-Lipoxygenase activating protein (FLAP), Macrophage/Adipocyte Fatty acid binding protein (aP2), IFN-γ, IL-4, ICAM, VCAM, MMPs, TNFα and IL-1β.

3. The method as claimed in claim 1 , wherein the disease is treated with a therapeutically effective amount of a combination of:

from 30% to 70% by weight of the combination of the Boswellia serrata extract selectively enriched in 3-O-acetyl-11-keto-β-boswellic acid (AKBA); and

from 30% to 70% by weight of the combination of the Boswellia serrata resin non-acidic, water-immiscible organic solvent extract (BNRE) obtained by selectively removing acidic compounds from the Boswellia serrata gum resin extract.

4. The method as claimed in claim 1 , wherein the Boswellia serrata resin non-acidic, water-immiscible organic solvent extract comprises at least three compounds selected from the group consisting of guiol, nephthenol, serratol, diterpene X, lupeol, olean-12-ene-3β-ol, olean-12-ene-3α-ol, lanosta-8,24-diene-3α-ol and urs-12-ene-3α-ol.

5. The method as claimed in claim 1 , wherein the selectively enriched Boswellia serrata extract contains AKBA in a concentration of 10% to 100% by weight.

6. The method as claimed in claim 1 , wherein the selectively enriched Boswellia serrata extract contains AKBA in a concentration of 25% to 95% by weight.

7. The method as claimed in claim 1 , wherein the selectively enriched Boswellia serrata extract contains AKBA in a concentration of 25% to 45% by weight.

8. The method as claimed in claim 1 , wherein the Boswellia serrata non-acidic resin extract (BNRE) is obtained by:

extraction of gum resin of Boswellia serrata with a water immiscible organic solvent;

filtering the extract to remove undissolved resin material to provide an organic solvent extract;

washing the organic solvent extract with an aqueous alkali solution to produce an organic layer; and

evaporating organic solvent from the organic layer to obtain an oily residue; and

removing volatile compounds from the oily residue under high vacuum and high temperature to obtain the Boswellia serrata resin non-acidic, water-immiscible organic solvent (BNRE).

Assignments (3)
CHANGE OF NAME Recorded Aug 18, 2025
From: LAILA NUTRACEUTICALS
To: LAILA NUTRA PRIVATE LIMITED
Reel/Frame 072508/0229 →
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE'S ADDRESS PREVIOUSLY RECORDED AT REEL: 049255 FRAME: 0697. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Jun 3, 2019
From: GOKARAJU, GANGA RAJU; GOKARAJU, RAMA RAJU; GOKARAJU, VENKATA KANAKA RANGA RAJU; GOLAKOTI, TRIMURTULU; BHUPATHIRAJU, KIRAN; ALLURI, VENKATA KRISHNA RAJU
To: LAILA NUTRACEUTICALS
Reel/Frame 049344/0627 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 22, 2019
From: GOKARAJU, GANGA RAJU; GOKARAJU, RAMA RAJU; GOKARAJU, VENKATA KANAKA RANGA RAJU; GOLAKOTI, TRIMURTULU; BHUPATHIRAJU, KIRAN; ALLURI, VENKATA KRISHNA RAJU
To: LAILA NUTRACEUTICALS
Reel/Frame 049255/0697 →
Priority Claims (1)
IN 2229/CHE/2008 · Sep 15, 2008 · national
Continuity (3)
Division 14735360 · Jun 10, 2015
Continuation 13062066
Related Publication 20190175678A1 · Jun 13, 2019